Bayer Trasylol To Receive FDA Advisory Cmte. Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling changes will likely be the subject of the Sept. 21 advisory committee meeting for aprotinin injection.
You may also be interested in...
Trasylol Public Health Advisory Cites Kidney, Heart Attack, Stroke Risks
FDA will convene an advisory committee meeting to discuss the risks and benefits of Bayer's transfusion-sparing agent following risk reports.
India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.
Indian Health Minister Asks Novartis to Stand Down On Gleevec Patent Fight
Indian regulators threaten compulsory licensing of the oncologic, but Novartis says it has no plans to end its bid for patent protection.